Zoekresultaten - You searched for Collaborations

109 results

Industrial automation companies from Baden-Württemberg looking for collaborations

Read more

BioFIT 2017

Read more

GAMIAN-Europe & CMAST announce collaborative partnership

Read more

Ablynx strongly believes unsolicited conditional proposal from Novo Nordisk fundamentally undervalues the company and its future prospects

Read more

Ablynx appoints dr. Robert Friesen as Chief Scientific Officer

Read more

Ablynx announces 2017 full year results

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

Ablynx proposes appointment of Mrs. Hilde Windels as a new independent director

Read more

Immunity for Health 2017

Read more

Ablynx announces 2017 half year results and year-to-date business update

Read more

flanders.bio's Healthcare Leaders Dinner

Read more

Imec Designs and Fabricates World-First Miniature Neural Probe for Simultaneous Recording of Multiple Brain Regions at Neuronal Resolution

Read more

Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE

Read more

Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests

Read more

BIO Asia International Conference

Read more

Will 2018 be the year of biotech M&A? - An analysis by KBC Securities

Read more

BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials

Read more

flanders.bio - Janssen Pharma Partner Day 2018: Innovate – Connect – Collaborate!

Read more

argenx reports fourth quarter business update and full year 2017 financial results

Read more

Biocartis Establishes R&D Center in the US

Read more

Biocartis announces 2017 results and 2018 outlook

Read more

Hamilton Robotics first company to join the UgenTec’s new Molecular Automation Network

Read more

VIB presents its 2017 annual results and confirms its reputation as global player

Read more

Biocartis Q1 2018 business update

Read more

argenx receives milestone payment from strategic collaboration with Shire

Read more

argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody

Read more

Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla(TM) Platform in China

Read more

BioFIT 2018

Read more

argenx reports third quarter 2018 financial results and provides business update

Read more

BioTrinity 2019

Read more

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Read more

CMAST is stepping into a strategic partnership with FlandersBio

Read more

MDxHealth Epigenetic Biomarkers Identify Men at Increased Risk of Prostate Cancer Recurrence

Read more

3th BMIC Congress

Read more

13th International Conference on Renewable Resources & Biorefineries

Read more

Ablynx announces warrant exercise

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP

Read more

argenx reports first quarter 2017 financial results and provides business update

Read more

ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

Read more

Ablynx to present at upcoming USA Investor Conferences

Read more

SLims by Genohm integrated with Pathomation’s PMA.core

Read more

Novel Nanobody to start clinical development in osteoarthritis - ablynx to receive €15 Million milestone payment

Read more

Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors

Read more

Celyad obtains additional US patent for cancer treatment

Read more

Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, at the annual European Congress of Rheumatology

Read more

Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference – San Diego, June 19- 23, 2017

Read more

REGMED Europe

Read more

Internationalisation

Read more

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Read more

Ablynx achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, New Jersey, USA

Read more

Publication in accordance with art. 14 of the Belgian Law regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx & Sanofi enter into a strategic collaboration to develop nanobody product candidates

Read more

Ablynx receives fast track designation from the FDA for Caplacizumab for the treatment of acquired TTP

Read more

Ablynx will announce its 2017 half year results with webcast on 24 august 2017

Read more

argenx reports second quarter business update and half-year 2017 financial results

Read more

Ablynx: publication in accordance with article 14 of the Belgian law regarding the publication of major shareholdings

Read more

Ablynx to present at upcoming investor conferences in London

Read more

Ablynx Announces Warrant Exercise

Read more

Mithra announces 2017 half year results

Read more

Ablynx announces positive topline results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP

Read more

Ablynx files registration statement for a proposed global offering

Read more

flanders.bio joins forces with FIT to support the internationalisation of Flanders’ economy

Read more

Ablynx - Publication in accordance with art.14 of the Belgian law of 2/05/2017 regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx - Publication in accordance with art.14 of the Belgian Law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx establishes subsidiary in the USA and appoints a general manager

Read more

Ablynx announces launch of proposed global offering

Read more

Ablynx prices $200 million Initial Public Offering in the United States

Read more

Suspension of trading in Ablynx shares on Euronext Brussels

Read more

Ablynx - Notice in Relation to the Convertible bonds due May 2020

Read more

Ablynx announces full exercise of underwriters' option to purchase additional shares and end of stabilization period

Read more

Ablynx closes $200 Million Initial Public Offering in the United States

Read more

Ablynx closes on underwriters' option to purchase $30 million of additional shares in the U.S. initial public offering

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Correction of Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law) (1)

Read more

Ablynx to present at upcoming investor conferences in London and Paris

Read more

Ablynx: publication regarding the publication of major shareholdings

Read more

Ablynx: publication regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx announces results for the first nine months of 2017 and a year-to-date business update

Read more

Ablynx - Results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP selected for presentation in the late-breaking abstracts session at the 2017 ASH annual meeting

Read more

Ablynx - Publication in accordance with §14 of the Belgian Law

Read more

Ablynx to host webcast about Phase III Hercules Study

Read more

Ablynx reports additional clinically important benefits of Caplacizumab from its Phase III Hercules Study in acquired TTP

Read more

Ablynx announces positive data from its Japanese ethno-bridging study of Caplacizumab

Read more

Ablynx - notice in relation to waiver of lock-up restriction

Read more

Ablynx to present at the 36th annual J.P. Morgen Healthcare conference

Read more

Ablynx announces board changes

Read more

Sanofi to acquire Ablynx for €3.9 Billion

Read more

Networking - 01/03/2018

Read more

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Read more

Ablynx commences dosing in its Phase II Study of ALX-0171 in hospitalised Japanese infants with a RSV infection

Read more

Previously announced tender offers by Sanofi to acquire Ablynx will commence on april 4, 2018

Read more

CMAST to present at a Veeva seminar on modernizing quality management / April 10th, 2018 / Paris, France

Read more

Ablynx teams up with AIM for the design and implementation of its commercial supply chain for caplacizumab

Read more

Ablynx completes patient recruitment in the Phase IIb Respire Study of its inhaled anti-RSV Nanobody ALX-0171

Read more

Human Biotech & Animal Health Business Partnering Summit

Read more

Sanofi and Ablynx announce the successful results of the initial tender offer period for ablynx and commencement of squeeze-out tender period

Read more

Ablynx: Notice In Relation To The Convertible Bonds Due May 2020

Read more

CMAST to participate in the bio international convention (Boston, us - 4-7 june, 2018)

Read more

Sanofi complets its acquisition of Ablynx following the expiration of the squeeze-out procedure

Read more

CMAST attends the 2nd General Assembly of RESCEU; a European project focusing on the battle against RSV (June 21st-22nd, Oxford - UK)

Read more

CMAST: Horizon Europe – looking at the future or building on the past?

Read more

Galapagos: Positive trial results with filgotinib in psoriatic arthritis and ankylosing spondylitis both published in the lancet

Read more

Emerging Applications of Microbes

Read more

New project launched to harmonize Clinical Data and develop a 21st Century Ecosystem for Real World Health Research in Europe

Read more

Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property

Read more

argenx reports first quarter 2018 financial results and provides business update

Read more

flanders.bio - CMAST Partner Day: Realizing Life Science Innovation with Impact

Read more